Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, "Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkin's Lymphoma of any of the Phase 3 Non-Hodgkin's Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007."

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkin's Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patient's own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Newport ... that Siddhartha Kadia, Ph.D. has joined the company,s ... Chief Executive Officer and a director of Evans ... laboratory testing, evaluation and analytical services to companies ... Prior to joining Evans Analytical Group, Dr. ...
(Date:12/19/2014)... 19, 2014 In today,s increasingly global ... presence to reflect the needs of a global ... meet the needs of key stakeholders while recognizing ... According to recent research by benchmarking firm, ... participating companies averaged more than $100,000 in annual ...
(Date:12/19/2014)... Dec. 18, 2014 Somewhere between dropping five ... was forgotten. But Audicus , a next-generation hearing ... this new year. Hearing loss is the ... population, though it is often unaddressed. Forty-eight million Americans ... a hearing aid, mainly due to price. Hearing aids ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2
... Nov. 18, 2010 Royal Philips Electronics (NYSE: ... major manufacturer of neonatal medical equipment, announced today ... customers with a more complete portfolio of perinatal ... monitoring, apnea home monitoring, neonatal incubators and warmers, ...
... 18, 2010 Cardinal Health (NYSE: CAH ... leading pharmaceutical distributor serving the New York metropolitan area, ... significantly expand its ability to serve retail independent pharmacies ... Health expects the transaction to be neutral to slightly ...
Cached Medicine Technology:Philips and Atom Medical Corporation Announce Strategic Alliance to Provide a Complete Neonatal and Perinatal Offering 2Philips and Atom Medical Corporation Announce Strategic Alliance to Provide a Complete Neonatal and Perinatal Offering 3Cardinal Health To Acquire Kinray for $1.3 Billion 2Cardinal Health To Acquire Kinray for $1.3 Billion 3Cardinal Health To Acquire Kinray for $1.3 Billion 4Cardinal Health To Acquire Kinray for $1.3 Billion 5
(Date:12/20/2014)... 2014 Recently, VogueQueen.com, a leading wedding ... Big Sale Online for 2015. Great discounts are ... and old consumers can get a discount, up to ... company’s website before January 30, 2015. , VogueQueen.com has ... launched a prom dress promotion. Many customers worldwide like ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, ... The company has recently updated its official blog with ... season, Angeldress Blog has recommended some new ... prides itself in offering a huge selection of elegant ... company’s outfits are very carefully selected based on the ...
(Date:12/20/2014)... CA (PRWEB) December 20, 2014 Atore, ... Innovation company just launched first birthday focused portal on ... “MERRY BIRTHDAY MESSAGE” launched in both US and Japan. ... BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY ... everyone’s birthday around the world. , Features, Choose from ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Recently, AngelWeddingDress.com ... Christmas Discount ”) for the coming Christmas. In the ... to 80% off. , “We have something special for ... for the holiday season. Moreover, our new collections of ... models are offered now at greatly discounted prices. Visit ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men ... and other serious side effects will be consolidated in ... coordinated pretrial proceedings, Wright & Schulte LLC reports. The ... order Friday to transfer 21 Xarelto lawsuits and over ... to the Louisiana district court for coordination by Judge ...
Breaking Medicine News(10 mins):Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... effective. Researchers from the Walter Reed Army Medical Center ... higher dose of a synthetic cholesterol-lowering drug not only ... than those given a regular dose// of a similar ... in the main neck arteries supplying blood to the ...
... of evidence that adult health is set to a considerable ... may start earlier in pregnancy than previously believed. According to ... bones// at 24weeks had higher blood pressure at the age ... ,Understanding how life in the womb influences later health has ...
... with sleep-disordered breathing suffer from behavioral and emotional ... improvement in behavior and quality of life after ... preschool and school-aged children suffer from pediatric obstructive ... is often associated with nighttime breathing difficulties and ...
... at the University of Stanford, have discovered the point ... lose the ability to repair themselves. The investigators said ... this regeneration loss and speed nerve cell growth. ... they can study any disease that causes// the brain ...
... of removing cancerous kidneys through a small incision with ... and instuments. This is the hand-assisted Laproscopic technique, which ... standard laproscopic procedure. ,The research, being presented at the ... from the University of Michigan(U-M) Health System,// U.S., may ...
... ways to repair damaged arteries and ailing hearts have coaxed ... vessels. According to Robert Langer, leader of a laboratory team ... time human embryonic stem cells have been nurtured to the ... nourish the body.// ,But it is not likely to ...
Cached Medicine News:Health News:Cholesterol in low levels are good 2Health News:Womb may have impact upon Blood Pressure 2Health News:Womb may have impact upon Blood Pressure 3Health News:Tonsillectomy improves quality of life 2Health News:Brain Cell Repair Loss disclosed 2Health News:Lessening operation and recovery time 2Health News:Stem cells form blood vessels 2Health News:Stem cells form blood vessels 3
... For practices that ... solution, the Burdick Vision,Premier ... powerful,diagnostic tool. The Vision ... choices and a,more comprehensive ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
The compact, simple-to-use ECG for medical professionals....
Medicine Products: